In yet another deal to diversify its portfolio, Roche has entered into a licensing and collaboration agreement with Monte Rosa Therapeutics to develop small molecule-based therapeutics for challenging targets in major disease areas, including oncology and neurodegeneration. The deal, worth up to over US$2 B, will provide Roche with access to Monte Rosa’s molecular glue degrader platform, known as QuEEN (Quantitative and Engineered Elimination of Neosubstrates). Interestingly, the deal comes less than a month after Roche signed a similar molecular glue focused deal with Boston-based Orionis Biosciences.